Cargando…

Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer

Hyperactivation of PI3K/AKT/mTOR and MAPK/MEK/ERK signaling pathways is commonly observed in many cancers, including triple-negative breast cancer (TNBC) and melanoma. Moreover, the compensatory upregulation of the MAPK/MEK/ERK pathway has been associated with therapeutic resistance to targeted inhi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhizhu, Richmond, Ann, Yan, Chi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266842/ https://www.ncbi.nlm.nih.gov/pubmed/35806358 http://dx.doi.org/10.3390/ijms23137353

Ejemplares similares

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
por: Li, Qingfang, et al.
Publicado: (2022)

The Roles of PI3K/AKT/mTOR and MAPK/ERK Signaling Pathways in Human Pheochromocytomas
por: Du, Juan, et al.
Publicado: (2016)

MAPK6-AKT signaling promotes tumor growth and resistance to mTOR kinase blockade
por: Cai, Qinbo, et al.
Publicado: (2021)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
por: Chappell, William H., et al.
Publicado: (2011)

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012)

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
por: Butler, Dominika E., et al.
Publicado: (2017)

Apatinib induces apoptosis and autophagy via the PI3K/AKT/mTOR and MAPK/ERK signaling pathways in neuroblastoma
por: Yu, Xiying, et al.
Publicado: (2020)

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
por: Steelman, Linda S., et al.
Publicado: (2011)

Biphasic regulation of osteoblast development via the ERK MAPK–mTOR pathway
por: Kim, Jung-Min, et al.
Publicado: (2022)

Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways in Merkel cell carcinoma
por: Temblador, Arturo, et al.
Publicado: (2022)

Tanshinone IIA induces autophagy in colon cancer cells through MEK/ERK/mTOR pathway
por: Qian, Jun, et al.
Publicado: (2020)

Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma
por: Ewald, Florian, et al.
Publicado: (2015)

The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors
por: Zhang, Zhizhu, et al.
Publicado: (2021)

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
por: McCubrey, James A., et al.
Publicado: (2012)

The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas—New Potential Therapeutic Approach—A Systematic Review
por: Derwich, Aleksandra, et al.
Publicado: (2023)

Gemcitabine resistance in breast cancer cells regulated by PI3K/AKT-mediated cellular proliferation exerts negative feedback via the MEK/MAPK and mTOR pathways
por: Yang, Xiao Li, et al.
Publicado: (2014)

Roles of Akt and ERK in mTOR-Dependent Antidepressant Effects of Vanillic Acid
por: Chuang, Han-Wen, et al.
Publicado: (2020)

Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways
por: Cui, Shu-Xiang, et al.
Publicado: (2016)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011)

Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK Inhibition
por: Atanasova, Velina S., et al.
Publicado: (2023)

Leptin Stimulates Prolactin mRNA Expression in the Goldfish Pituitary through a Combination of the PI3K/Akt/mTOR, MKK(3/6)/p(38)MAPK and MEK(1/2)/ERK(1/2) Signalling Pathways
por: Yan, Aifen, et al.
Publicado: (2017)

The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
por: Shorning, Boris Y., et al.
Publicado: (2020)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Mutant HRAS as novel target for MEK and mTOR inhibitors
por: Kiessling, Michael K., et al.
Publicado: (2015)

Aldose reductase interacts with AKT1 to augment hepatic AKT/mTOR signaling and promote hepatocarcinogenesis
por: Zhao, Jia-Xing, et al.
Publicado: (2017)

Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin
por: Ou, Da-Liang, et al.
Publicado: (2014)

Fibroblast Growth Factor 2 Induces E-Cadherin Down-Regulation via PI3K/Akt/mTOR and MAPK/ERK Signaling in Ovarian Cancer Cells
por: Lau, Man-Tat, et al.
Publicado: (2013)

CK-3, A Novel Methsulfonyl Pyridine Derivative, Suppresses Hepatocellular Carcinoma Proliferation and Invasion by Blocking the PI3K/AKT/mTOR and MAPK/ERK Pathways
por: Wu, Qiong, et al.
Publicado: (2021)

Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
por: Lelliott, Emily J., et al.
Publicado: (2021)

mTOR Activation by PI3K/Akt and ERK Signaling in Short ELF-EMF Exposed Human Keratinocytes
por: Patruno, Antonia, et al.
Publicado: (2015)

An immunomodulatory signature of responsiveness to immune checkpoint blockade therapy
por: Shen, Hongru, et al.
Publicado: (2020)

Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Regulates Neurite Outgrowth Through the Activation of Akt/mTOR and Erk/mTOR Signaling Pathways
por: Wen, Wen, et al.
Publicado: (2020)

Correction: Fibroblast Growth Factor 2 Induces E-Cadherin Down-Regulation via PI3K/Akt/mTOR and MAPK/ERK Signaling in Ovarian Cancer Cells
por: Lau, Man-Tat, et al.
Publicado: (2013)

Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways
por: Zhang, Leilei, et al.
Publicado: (2017)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma
por: Schreck, Karisa C, et al.
Publicado: (2020)

Gefitinib induces lung cancer cell autophagy and apoptosis via blockade of the PI3K/AKT/mTOR pathway
por: ZHAO, ZHONG-QUAN, et al.
Publicado: (2016)

Deciphering Combinations of PI3K/AKT/mTOR Pathway Drugs Augmenting Anti-Angiogenic Efficacy In Vivo
por: Sasore, Temitope, et al.
Publicado: (2014)

TNFα Signaling Regulates Cystic Epithelial Cell Proliferation through Akt/mTOR and ERK/MAPK/Cdk2 Mediated Id2 Signaling
por: Zhou, Julie X., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gmr45luf72n8blucpe0k8fm0o6